MedWatch

A part of Watch Media

Danish scientists raise alarm after discovering link between Bayer drug and brain cancer

The drug Androcur from German pharmaceutical giant Bayer has resulted in severe side effects on several occasions, when patients developed a lethal type of brain cancer after receiving the drug. Researchs raise alarm and call for the DMA to reassess its recommendation, while Bayer is silent.

Photo: Bayer / PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

German pharmaceutical company Bayer might soon be the center of an impending scandal.

Researchers at Copenhagen-based hospital Rigshospitalet have documented a clear link between the drug Androcur (cyproterone acetate) from Bayer and a serious type of cancerous brain tumor known as meningioma, which are potentially lethal tumors in the brain membrane that usually require surgical removal.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

  1. EMA begins rolling review of another Covid-19 vaccine
  2. AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  3. Y-mabs CEO has big ambitions: Wants to create the Tesla of biotech
  4. CSL eyeing acquisition candidate in Vifor Pharma
  5. Contact with consumers will secure continued growth in China, says Sonova
  6. "Real world" patient data documents the long-term effects of ALK vaccines
  7. President of the European Commission puts mandatory vaccination on the table
  8. Danish Medicines Council could be a roadblock for sclerosis drug Kesimpta
  9. European reference laboratory network to ensure better data across the region
  10. Headhunter calls outgoing Leo Pharma CEO a "flop"
  11. Genmab pipeline hype makes investment bank uneasy
  12. Leo Pharma looks for CEO with capital markets experience ahead of IPO
  13. Coloplast starts testing sensor-based product for ostomy leakage
  14. EU drugs agency can clear Omicron shot in 4 months if needed
  15. EU countries approve new powers for disease prevention agency

Jobs

See all jobs

See all jobs